β-hydroxy-β-methylbutyrate enhances anti-PD1 immunotherapy in a mouse model of pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Etigunta, Suhas K. [1 ]
Coleman, Michael F. [1 ]
Pfeil, Alex J. [1 ]
Lashinger, Laura M. [2 ]
Cui, Zhengrong [2 ]
Hursting, Stephen D. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Texas Austin, Austin, TX 78712 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1565
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model
    Semba, Taro
    Tabata, Kimiyo
    Ozawa, Yoichi
    Miyano, Saori Watanabe
    Matsui, Junji
    Funahashi, Yasuhiro
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
    Yu, Chao
    Zhang, Xinyi
    Wang, Min
    Xu, Gaoxin
    Zhao, Siqi
    Feng, Yongheng
    Pan, Chao
    Yang, Weijun
    Zhou, Jin
    Shang, Longcheng
    Ma, Yong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma
    Henry, Kelly E.
    Mack, Kyeara N.
    Nagle, Veronica L.
    Cornejo, Mike
    Michel, Adam O.
    Fox, Ian L.
    Davydova, Maria
    Dilling, Thomas R.
    Pillarsetty, Nagavarakishore
    Lewis, Jason S.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 2026 - 2034
  • [44] Targeting leucine-rich repeat serine/threonine- protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy
    Sun, Kang
    Zhang, Xiaozhen
    Lao, Mengyi
    He, Lihong
    Wang, Sicheng
    Yang, Hanshen
    Xu, Jian
    Tang, Jianghui
    Hong, Zhengtao
    Song, Jinyuan
    Guo, Chengxiang
    Li, Muchun
    Liu, Xinyuan
    Chen, Yan
    Zhang, Hanjia
    Zhou, Jingxing
    Lin, Jieru
    Zhang, Sirui
    Hong, Yifan
    Huang, Jinyan
    Liang, Tingbo
    Bai, Xueli
    MOLECULAR THERAPY, 2023, 31 (10) : 2929 - 2947
  • [45] Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer
    Zhu Alexander Cao
    Dylan Daniel
    Douglas Hanahan
    BMC Cancer, 2
  • [46] Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer
    Cao, ZA
    Daniel, D
    Hanahan, D
    BMC CANCER, 2002, 2 (1)
  • [47] Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
    Shklovskaya, Elena
    Pedersen, Bernadette
    Stewart, Ashleigh
    Simpson, Jack O. G.
    Ming, Zizhen
    Irvine, Mal
    Scolyer, Richard A.
    Long, Georgina, V
    Rizos, Helen
    CANCERS, 2022, 14 (19)
  • [48] Targeting vasoactive intestinal peptide receptor signaling enhances T-cell mediated anti-tumor response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
    Passang, Tenzin
    Ravindranathan, Sruthi
    Li, Jian-Ming
    Wang, Shuhua
    Ware, Michael Brandon
    Zhang, Hanwen
    Lesinski, Gregory B.
    Waller, Edmund K.
    CANCER RESEARCH, 2022, 82 (22) : 115 - 116
  • [49] Immune modulatory effects of chemotherapy increase the effectiveness of anti-PD1 immunotherapy in a poorly immunogenic murine model of osteosarcoma
    Ladle, Brian H.
    Phillips, Maggie J.
    Yu, Colburn
    Gamper, Christopher J.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [50] Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma
    Li, Qiong
    Qin, Siyuan
    Tian, Hailong
    Liu, Ruolan
    Qiao, Ling
    Liu, Shanshan
    Li, Bowen
    Yang, Mei
    Shi, Jiayan
    Nice, Edouard C.
    Li, Jingquan
    Lang, Tingyuan
    Huang, Canhua
    SMALL, 2023, 19 (23)
12345